Type of security: Stock
Sector: Capital Goods
Market Capitalization: 2.39 B
The data is delayed by 15 minutes.
CPHD is in the long-term up 731% in 27 years.
Description: Cepheid, a molecular diagnostics company, develops, manufactures, and markets integrated systems for testing in the clinical and non-clinical markets; and for application in legacy non-clinical market. Its systems enable molecular testing for organisms and genetic-based diseases by automating manual laboratory procedures. The company offers GeneXpert system that integrates sample preparation in addition to DNA amplification and detection; and SmartCycler system, which integrates DNA amplification and detection to allow rapid analysis of a sample. The GeneXpert system is designed for reference laboratories, hospital central laboratories, and satellite testing locations, such as emergency departments and intensive care units within hospitals, as well as physician offices and other alternate site laboratories. It also provides GeneXpert Infinity System for high volume testing. The company offers GeneXpert system for testing in the areas of healthcare associated infections, critical infectious disease, sexual hea
|Shares Outstanding||72.89 M||EPS||-0.69||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||13.85%||Sales Growth - Q/Q||0.85%||P/E||-76.74|
|P/E To EPS Growth||P/S||4.82||P/BV||6.35||Price/Cash Per Share||7.7|
|Price/Free Cash Flow||-63.25||ROA||-4.91%||ROE||-10.61%||ROI||-5.9%|
|Current Ratio||4.2||Quick Ratio||3.14||Long Term Debt/Equity||0.66||Debt Ratio||0.35|
|Gross Margin||52.12%||Operating Margin||-4.67%||Net Profit Margin||-8.05%||Dividend Payout Ratio|
|Cash From Financing Activities||20.57 M||Cash From Investing Activities||-13.18 M||Cash From Operating Activities||7.92 M||Gross Profit||63.1 M|
|Net Profit||-16.73 M||Operating Profit||-10.75 M||Total Assets||823.88 M||Total Current Assets||548.35 M|
|Total Current Liabilities||141.79 M||Total Debt||282.98 M||Total Liabilities||449.39 M||Total Revenue||132.47 M|
|High 52 week||52.95||Low 52 week||25.64||Last close||52.95||Last change||0%|
|RSI||58.93||Average true range||3.86||Beta||0.22||Volume|
|Simple moving average 20 days||0.14%||Simple moving average 50 days||2.59%||Simple moving average 200 days||44.93%|
|Performance Week||0%||Performance Month||0.38%||Performance Quart||48.15%||Performance Half||105.23%|
|Performance Year||48.03%||Performance Year-to-date||0%||Volatility daily||0.12%||Volatility weekly||0.27%|
|Volatility monthly||0.56%||Volatility yearly||1.93%||Relative Volume||0%||Average Volume||2.11 M|
|New High||New Low|
2017-02-14 05:00:11 | These drug and medical device companies made the most payments to L.A. hospitals
2017-01-31 12:15:59 | Mario Gabelli Comments on Cepheid
2017-01-17 16:36:05 | Behind Danaher’s 4Q16 Revenue Estimates
2016-12-05 10:44:21 | Here is What Hedge Funds Think About Clear Channel Outdoor Holdings, Inc. CCO
2016-12-05 10:28:45 | 5 Healthcare Stocks Billionaires Are Buying
2016-12-03 17:30:35 | Is Chemed Corporation CHE Going to Burn These Hedge Funds?
2016-11-30 13:32:39 | Cepheid CPHD: What Smart Money Thinks about This Stock?
2016-11-15 13:04:11 | CEPHEID Financials
2016-11-03 16:28:32 | CEPHEID Files SEC form 10-Q, Quarterly Report
2016-10-28 16:51:33 | CEPHEID Files SEC form 8-K, Change in Directors or Principal Officers
2016-10-27 08:26:08 | 30 Minute Or Less Molecular Flu/RSV Test Now Available Outside The US
2016-10-27 08:00:00 | 30 Minute Or Less Molecular Flu/RSV Test Now Available Outside The US
2016-10-24 08:08:01 | CEPHEID Files SEC form 8-K, Other Events, Financial Statements and Exhibits
2016-10-24 07:47:11 | Medical Product Oct 25 Earnings Roster: BAX, RMD, CPHD, EW
2016-10-20 10:33:02 | Danaher DHR Q3 Earnings Top Estimates, Revenues Up Y/Y
2016-10-17 10:32:02 | What's in Store for Cepheid CPHD this Earnings Season?
2016-10-17 09:52:01 | Medical Stocks Q3 Earnings on Oct 18: JNJ, UNH, CPHD, ISRG
2016-10-14 09:33:01 | Exactech Enters Foot & Ankle Space with Vantage System
2016-10-13 08:54:12 | Exactech: Surgery Technology Studies Encourage, Stock Up
2016-10-12 08:21:12 | Patterson Companies & Heartland Dental Form Partnership
2016-10-11 10:06:16 | Why Danaher Is Relatively Immune from Growth Concerns in China
2016-10-10 09:20:01 | Cepheid: Commercial Launch of Xpert Bladder Cancer Monitor
2016-10-07 18:09:35 | Columbia Wanger Sold 2 Stakes in September
2016-10-07 07:36:11 | Baxter BAX: Portfolio Strong, Cyclophosphamide Sales Low
2016-09-26 13:34:05 | Proxy Statement Shows Danaher Faced Competition In Bid To Buy Cepheid
2016-09-20 12:56:40 | 5 Notable NASDAQ Names Notched 52-Week Highs on Monday
2016-09-16 12:58:16 | Why GenMark Diagnostics, Inc. Is Soaring Today
2016-09-16 09:21:01 | Cepheid Announces Expansion of Molecular C. Difficile Product
2016-09-14 10:10:02 | Cepheid's CPHD Shares March Higher, Can It Continue?
2016-09-13 15:18:00 | Lifshitz & Miller Law Firm Announces Investigation of AECOM, American Farmland Company, Centene Corp., Cepheid, Cray Inc., Echo Global Logistics, Inc., Ocular Therapeutix, Inc., and Pure Storage, Inc.
2016-09-12 10:21:00 | Cepheid CPHD Stock Downgraded to 'Neutral' at Baird
2016-09-10 00:01:00 | [$$] Charting the Market
2016-09-09 15:23:00 | Cepheid Acquisition May Not Be in the Best Interests of CPHD Shareholders
2016-09-08 10:55:06 | Cepheid – Value Analysis NASDAQ:CPHD : September 8, 2016
2016-09-08 08:07:12 | Will Cepheid's CPHD Buyout by Danaher be a Strategic Fit?
2016-09-07 18:04:05 | How Cepheid Fits Strategically into DHR’s Portfolio
2016-09-07 17:37:00 | Harwood Feffer LLP Announces Investigation of Cepheid